Tag: Biologics
Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...
The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore
“There are inconstancies across biosimilar classes right now”
Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets
Biocon Biologics appoints Sandoz as distributor for Adalimumab BS Subcutaneous Injection...
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases
Biocon Biologics concludes integration of acquired biosimilars business in 120 countries
Over 10 Emerging Markets along with Japan, Australia and New Zealand have transitioned in this final phase of the integration of the biosimilars business acquired from Viatris.
Biocon Biologics successfully completes integration of Viatris’ biosimilar business in 31...
In Europe, Biocon Biologics portfolio includes 7 biosimilars: Insulin Aspart and Insulin Glargine, Bevacizumab, Pegfilgrastim, Trastuzumab, Adalimumab, and Etanercept
Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...
In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)
Biocon Biologics announces divestment of two non-core branded formulations business units
The move is in line with the company’s strategy to sharpen focus on core therapy areas as a fully integrated biosimilars company
Biologics to garner $120 billion worth sales revenue by 2027, predicts...
Biologics are poised to emerge as dominating molecule type in solid tumor indication, overtaking innovative small molecules in terms of sales revenue, according to GlobalData
CPHI Annual Survey: India set to transform into an innovation focused...
India is also predicted to the see the fastest CAGR in biologicals over in the next 5-years, as it quickly builds a bio CDMO base
Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Continuing to expand its global footprint, the company has completed the integration of the acquired biosimilars business from Viatris in North America (United States and Canada) effective September 1, 2023